Comprehensive analysis of protein phosphorylation in immune cells from patients under the administration of the tyrosine kinase inhibitor dasatinib

Comprehensive analysis of protein phosphorylation in immune cells from patients under the administration of the tyrosine kinase inhibitor dasatinib - Comprehensive analysis of the immunomodulatory effects of dasatinib

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000010651

Enrollment

Registered

2013-06-01

Start date

2013-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic myelogenous leukemia Philadelphia chromosome-positive acute lymphoblastic leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients of CML or Ph-positive ALL who are 20 years of age or more 2) Patients who are going to take or are taking dasatinib, imatinib, or nilotinib 3) Patients from whom informed consent has been obtained using documents

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Proportion of each leukocyte fraction in blood Phosphorylation of intracellular proteins in each leukocyte fraction	—

Countries

Japan

Contacts

Public ContactToshio Kitawaki

Graduate School of Medicine, Kyoto University Department of Hematology and Oncology

kitawaki@kuhp.kyoto-u.ac.jp

Outcome results